(Q38032867)

27 August 2017

title

Are cancer trials valid and useful for the general surgeon and surgical oncologist? (English)

1 reference

27 August 2017

Waddah B Al-Refaie

1

1 reference

27 August 2017

Selwyn M Vickers

series ordinal

2

1 reference

27 August 2017

publication date

1 January 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

46

1 reference

27 August 2017

page(s)

269-281

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

27 August 2017

1 reference

Commentary: Randomized Controlled Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Evidence-based practice requires evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Underrepresentation of patients 65 years of age or older in cancer-treatment trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Participation in cancer clinical trials: race-, sex-, and age-based disparities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

The American College of Surgeons Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Laparoscopy for colon cancer: state of the art.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Regulators, payers, and prescribers: can we fill the gaps?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

The opportunity cost of cancer care: a statement from NICE

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Delivering affordable cancer care in high-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Factors that predict the referral of breast cancer patients onto clinical trials by their surgeons and medical oncologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Does additional surgical training increase participation in randomized controlled trials?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Describing randomisation: patients' and the public's preferences compared with clinicians' practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Surgical and oncology trials for rectal cancer: who will participate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Clinicians' attitudes towards clinical trials of cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Eligibility and extrapolation in cancer clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Differences in clinical trial patient attributes and outcomes according to enrollment setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Who receives their complex cancer surgery at low-volume hospitals?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Cancer trials versus the real world in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Do hospital attributes predict guideline-recommended gastric cancer care in the United States?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Operative outcomes beyond 30-day mortality: colorectal cancer surgery in oldest old.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Guideline recommended gastric cancer care in the elderly: insights into the applicability of cancer trials to real world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Surgical oncology trials and surgeons in the real world!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI Cancer Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

Variations in gastric cancer care: a trend beyond racial disparities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YASU.2012.05.001

10.1016/J.YASU.2012.05.001

7 January 2021

Identifiers

DOI

1 reference

27 August 2017

1 reference